clofarabine has been researched along with Recrudescence in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (21.74) | 29.6817 |
| 2010's | 46 (66.67) | 24.3611 |
| 2020's | 8 (11.59) | 2.80 |
| Authors | Studies |
|---|---|
| Bierings, M; Boelens, JJ; Bresters, D; de Koning, CCH; Kollen, WJ; Lankester, AC; Lindemans, CA; Nierkens, S; Versluijs, AB | 1 |
| Bakkus, M; Beel, K; Bellido, M; Beverloo, HB; Biemond, BJ; Boersma, RS; Breems, DA; Cornelissen, JJ; de Haas, V; de Weerdt, O; Deeren, D; Fijnheer, R; Gadisseur, A; Halkes, CJM; Havelange, V; Homburg, CHE; Jaspers, A; Legdeur, MC; Legrand, O; Maertens, JA; Mazure, D; Rijneveld, AW; Selleslag, D; Sinnige, HAM; Terpstra, WE; Tick, LW; Triffet, A; van de Loosdrecht, AA; van der Holt, B; van der Velden, VHJ; van der Velden, WJFM; van der Wagen, LE; van Gelder, M; van Lammeren-Venema, D; van Sluis, GL | 1 |
| Bakunina, K; Breems, DA; Cloos, J; Cornelissen, JJ; de Wreede, LC; Gjertsen, BT; Koster, EAS; Löwenberg, B; Manz, MG; Ossenkoppele, GJ; Pabst, T; Passweg, J; Putter, H; Valk, PJM; van der Holt, B; Versluis, J | 1 |
| Agrawal, AK; Forlenza, CJ; Kernan, NA; Mauguen, A; Ramaswamy, K; Roshal, M; Shukla, N; Steinherz, PG; Sulis, ML; Trippett, T | 1 |
| Alatrash, G; Alousi, AM; Anderlini, P; Bassett, R; Champlin, RE; Chen, J; Daher, M; Hosing, C; Kawedia, J; Kebriaei, P; Ledesma, C; Lu, Y; Marin, D; Mehta, R; Nieto, Y; Olson, A; Oran, B; Popat, U; Qazilbash, M; Rondon, G; Saberian, C; Shpall, EJ; Thall, PF; Valdez, BC | 1 |
| Carulli, A; Catania, C; Connor, MP; Frey, NV; Freyer, CW; Gill, SI; Hexner, EO; Hollander, L; Loren, AW; Luger, SM; Mangan, JK; Martin, ME; McCurdy, SR; Perl, AE; Porter, DL; Pratz, KW; Smith, J; Stadtmauer, EA; Timlin, C; Zebrowski, AM | 1 |
| Andrade, AM; Carvalho, JL; Figueiredo, ACMG; Pogue, R; Teixeira, VR | 1 |
| Baruchel, A; Boëlle-Le Corfec, E; Geffriaud-Ricouard, C; Goto, H; Jeha, S; Pieters, R; Shin, HY | 1 |
| Alakel, N; Bornhäuser, M; Büttner, B; Ehninger, G; Knoth, H; Kramer, M; Middeke, JM; Oertel, R; Platzbecker, U; Röllig, C; Schetelig, J; Seeling, A; Sockel, K; Stölzel, F; von Bonin, M | 1 |
| Bossio, S; De Stefano, L; Gentile, M; Greco, R; Mazzone, C; Morabito, F; Morelli, R; Musolino, C; Palummo, A; Petrungaro, A; Recchia, AG; Uccello, G; Vigna, E | 1 |
| Andreeff, M; Bueso-Ramos, C; Cortes, JE; Coyle, M; Daver, N; DiNardo, CD; Futreal, PA; Garcia-Manero, G; Gumbs, C; Issa, GC; Jabbour, E; Jorgensen, J; Kadia, T; Kantarjian, HM; Konopleva, M; Little, L; Morita, K; Patel, KP; Pemmaraju, N; Ravandi, F; Sasaki, K; Song, X; Takahashi, K; Thornton, R; Tippen, S; Wang, F; Wang, S; Yan, Y; Zhang, J | 1 |
| Campbell, JD; Chapman, RH; Kumar, VM; McQueen, RB; Ollendorf, DA; Pearson, SD; Tice, JA; Whittington, MD | 1 |
| Alary, AS; Bouscary, D; Deau, B; Fontenay, M; Hermine, O; Kosmider, O; Mondesir, J; Sibon, D; Suarez, F; Tamburini, J; Willems, L | 1 |
| Cheng, YF; Liu, GL; Lu, AD; Suo, P; Wang, B; Wu, J; Zhang, LP; Zuo, YX | 1 |
| Allen, CE; Beaupin, LK; Bilgi, M; Coulter, D; Garrington, T; Hicks, MJ; Jones, J; McCavit, TL; McClain, KL; Moore, C; Rivera-Ortegón, F; Shaffer, L; Simko, SJ; Stork, L; Tran, HD; Turcotte, L; Welsh, EC | 1 |
| Kobos, R; Renaud, T; Shukla, N; Steinherz, LJ; Steinherz, PG | 1 |
| Balakrishnan, K; Borthakur, G; Burger, J; Cortes, J; Faderl, S; Feliu, J; Ferrajoli, A; Gandhi, V; Kadia, T; Kantarjian, HM; O'Brien, S; Plunkett, W; Ravandi, F; Thomas, DA | 1 |
| Advani, AS; Appelbaum, FR; Becker, M; Coutre, S; Elkins, S; McDonough, S; Mims, M; O'Donnell, M; Othus, M; Radich, J; Wood, B | 1 |
| Bilger, K; Blaise, D; Chevallier, P; de La Tour, RP; Delaunay, J; El-Cheikh, J; Furst, S; Guillaume, T; Labopin, M; Lioure, B; Michallet, M; Milpied, N; Mohty, M; Moreau, P; Socié, G; Tabrizi, R; Vigouroux, S | 1 |
| Abbi, KK; Claxton, DF; Ehmann, WC; Rybka, W | 1 |
| Imai, K | 1 |
| Aoki, T; Arakawa, Y; Hanada, R; Hayashi, M; Koh, K; Kubota, Y; Mori, M; Oyama, R | 1 |
| DeAngelo, DJ; McDonnell, AM; Roberts, DA; Steensma, DP; Stone, RM; Wadleigh, M | 1 |
| Dreyling, M; Engel, N; Fritsch, S; Haas, M; Hausmann, A; Hellmuth, JC; Herold, T; Hiddemann, W; Hubmann, M; Ledderose, G; Mumm, F; Prevalsek, D; Reibke, R; Rieger, CT; Tischer, J; Zoellner, AK | 1 |
| Einsele, H; Grigoleit, GU; Heuschmann, PU; Hupp, E; Kapp, M; Loeffler, C; Loeffler, J; Malzahn, U; Mielke, S; Stuhler, G | 1 |
| Alakel, N; Bethge, W; Bitz, U; Bornhäuser, M; Bug, G; Büttner, B; Ehninger, G; Hänel, M; Herbst, R; Klein, S; Knoth, H; Kramer, M; Middeke, JM; Morgner, A; Parmentier, S; Platzbecker, U; Röllig, C; Rösler, W; Schäfer-Eckart, K; Schaich, M; Schetelig, J; Sockel, K; Stölzel, F; Stuhler, G; Thiede, C; von Bonin, M | 1 |
| Cai, Z; Cheng, Y; Ding, L; Du, X; Fang, Y; Huang, X; Jia, Y; Li, Y; Lu, A; Lu, J; Tan, F; Wang, B; Wu, J; Yu, K; Zhang, L; Zhao, L; Zuo, Y | 1 |
| Ecstein-Fraisse, E; Inagaki, J; Kikuta, A; Koh, K; Kudo, K; Mizukami, H; Morimoto, T; Ogawa, C; Okamoto, Y | 1 |
| Chevallier, P; Françoise, M; Grain, A; Guillaume, T; Mohty, M; Rialland, F; Sirvent, A; Strullu, M | 1 |
| Ali, S; Burnett, AK; Burns, S; Cahalin, P; Clark, RE; Dennis, M; Freeman, S; Hills, RK; Kell, J; Milligan, D; Nielsen, OJ; Pocock, C; Russell, NH | 1 |
| Le Jeune, C; Thomas, X | 1 |
| Aoki, Y; Fujimura, J; Hoshino, A; Imai, K; Ishiwata, Y; Kajiwara, M; Kanegane, H; Mae, T; Matsumoto, K; Mitsuiki, N; Miyamoto, S; Mizutani, S; Morio, T; Nishimura, A; Takagi, M; Takikawa, K; Tanaka, M; Tomita, O; Tomizawa, D; Yanagimachi, M; Yasuhara, M | 1 |
| Cairoli, R; Greco, R; Grillo, G; Mancini, V; Marbello, L; Molteni, A; Ravano, E; Riva, M; Zucchetti, E | 1 |
| Brown, AW; McGregor, BA; Osswald, MB; Savona, MR | 1 |
| Nabhan, C | 1 |
| Capria, S; Fiocchi, C; Foà, R; Grammatico, S; Meloni, G; Vitale, A | 1 |
| Albano, E; Altman, A; Arceci, R; Bomgaars, L; Gaynon, P; Goldman, S; Jeha, S; Kadota, R; Luchtman-Jones, L; Razzouk, B; Rheingold, S; Ritchey, K; Rytting, M; Steinherz, L; Steinherz, P; Stine, K | 1 |
| Barberi, W; Bernardo, ME; Bertaina, A; Giraldi, E; Locatelli, F; Merli, P; Parasole, R; Pession, A; Rizzari, C; Testi, AM; Zecca, M | 1 |
| Einsele, H; Grigoleit, GU; Kapp, M; Mielke, S; Stuhler, G; Tan, SM; Topp, MS; Unzicker, C | 1 |
| Kobos, R; Shukla, N; Steinherz, L; Steinherz, PG | 1 |
| Abonour, R; Baute, J; Cox, E; Farag, SS; Jones, D; Kane, K; Nelson, RP; Robertson, MJ; Schwartz, JE; Secrest, A; Srivastava, S; Sullivan, C; Wood, LL | 1 |
| Advani, AS; Appelbaum, FR; Coutre, SE; Gundacker, HM; Lai, R; Lancet, JE; Mims, MP; Radich, JP; Sala-Torra, O; Slovak, ML; Stiff, PJ; Stuart, RK | 1 |
| Agura, E; Berryman, RB; Cooper, B; Fay, J; Holmes, H; Li, S; Maisel, C; Saracino, G; Tadic-Ovcina, M; Vance, E | 1 |
| Bitran, JD; Davis, N; Dewey, WM; Foss, S; Fried, W; Galvez, A; Nabhan, C; Tolzien, K; Venugopal, P | 1 |
| Kwong, YL; Lee, HK; Leung, AY; Liu, HS; Sim, J; Tse, E; Yip, SF | 1 |
| Appelbaum, FR; Becker, P; Estey, E; Hendrie, P; Knoebel, RW; McQuary, A; Petersdorf, S | 1 |
| Caswell, M; Connor, P; Cummins, M; Kearns, PR; Mitchell, C; Motwani, J; O'Connor, D; Sibson, K; Taj, M; Vora, A; Wynn, R | 1 |
| Bautista, F; Del Mar Andres, M; Fernandez-Navarro, JM; Moreno, L; Tasso, M; Verdeguer, A | 1 |
| Baker, SD; Campana, D; Christensen, R; Coustan-Smith, E; Furmanski, BD; Heym, KM; Inaba, H; Li, L; Mascara, GP; Onciu, M; Pounds, SB; Pui, CH; Ribeiro, RC; Rubnitz, JE; Shurtleff, SA | 1 |
| Barry, E; Borowitz, MJ; Carroll, WL; Cooper, T; Dahl, G; Gaynon, PS; Hijiya, N; Isakoff, MS; Jeha, S; Kadota, R; Maloney, K; Paul, JA; Shen, V; Silverman, LB; Steinherz, PG; Thomson, B; Thottassery, JV | 1 |
| Buresova, L; Dvorakova, D; Jeziskova, I; Mayer, J; Racil, Z; Razga, F; Timilsina, S; Toskova, M | 1 |
| Artz, AS; Del Cerro, P; Godley, LA; Kline, J; Larson, RA; Nguyen, V; O'Donnell, PH; Odenike, O; Rich, E; Stock, W; van Besien, K | 1 |
| Amin, C; Barr, ND; Chiu, WM; Foster, MC; Ivanova, A; Richards, KL; Shea, T; van Deventer, HW; Voorhees, PM; Whitman, J | 1 |
| Barisone, E; Bertorello, N; Calvillo, M; De Rossi, G; Dufour, C; Lo Nigro, L; Luciani, M; Messina, C; Miano, M; Micalizzi, C; Parasole, R; Petruzziello, F; Pistorio, A; Putti, MC; Varotto, S; Ziino, O | 1 |
| Avigan, D; Collins, R; Craig, M; Faderl, S; Ganguly, S; Goldberg, S; Greiner, J; Hari, P; Huebner, D; Jagasia, M; Kantarjian, HM; Kovacsovics, T; Maris, M; Ravandi, F; Recher, C; Rizzieri, D; Schiller, G; Seiter, K; Stuart, R; Vasconcelles, M; Vey, N; Wang, ES; Wetzler, M | 1 |
| Carraway, HE; Gladstone, DE; Gore, SD; Greer, JM; Karp, JE; Levis, MJ; McDevitt, MA; Pratz, KW; Ricklis, RM; Showel, MM; Smith, BD; Yun, HD; Zeidan, AM | 1 |
| Abd Elmoneim, A; Arceci, RJ; Boklan, J; Cooper, T; Gore, L; Narendran, A; Ricklis, RM; Rolla, K; Scott, T | 1 |
| Angelucci, E; Biagiotti, C; Borin, L; Bosi, A; Caracciolo, F; Cutini, I; Fanci, R; Gianfaldoni, G; Longo, G; Mannelli, F; Pogliani, EM; Romani, C; Scappini, B; Simonetti, F; Susini, MC | 1 |
| Szer, J | 1 |
| Abramson, JS; Barnes, JA; Brown, JR; Feng, Y; Fisher, DC; Hochberg, EP; Jacobsen, ED; Neuberg, DS; Takvorian, RW | 1 |
| Cortes, J; Craig, A; Davis, J; Du, M; Faderl, S; Freireich, EJ; Gandhi, V; Garcia-Manero, G; Giles, F; Jeha, S; Kantarjian, H; Keating, M; O'Brien, S; Plunkett, W; Shaked, Z; Verstovsek, S | 1 |
| Beran, M; Bonate, P; Cortes, J; Du, M; Estey, E; Estrov, Z; Faderl, S; Ferrajoli, A; Gandhi, V; Garcia-Manero, G; Giles, FJ; Kantarjian, H; Keating, M; Kwari, M; O'Brien, S; Plunkett, W; Wierda, W | 1 |
| Albano, E; Altman, A; Arceci, RJ; Bomgaars, LR; Franklin, J; Gaynon, PS; Goldman, S; Gordon, B; Griffin, T; Jeha, S; Kadota, R; Luchtman-Jones, L; Razzouk, BI; Rheingold, S; Ritchey, K; Rytting, M; Shen, V; Steinherz, L; Steinherz, P; Weitman, S | 1 |
| Bonate, PL; Du, M; Gandhi, V; Keating, MJ; Lerner, S; Nowak, B; Plunkett, W | 1 |
| McCarthy, CH; McDonald, LR | 1 |
| Higgins, EM; Mufti, GJ; Powell, S; Salisbury, JR; Williams, JS | 1 |
| Jeha, S; Meyers, PA; Steinherz, LJ; Steinherz, PG | 1 |
| Choi, J; Foss, F | 1 |
| Craig, CM; Schiller, GJ | 1 |
8 review(s) available for clofarabine and Recrudescence
| Article | Year |
|---|---|
A systematic review on the cost-effectiveness assessment of tisagenlecleucel for refractory or relapsing B-cell acute lymphoblastic leukemia (R/R B-ALL) treatment in children and young adults.
Topics: Child; Clofarabine; Cost-Benefit Analysis; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Receptors, Antigen, T-Cell; Recurrence; Young Adult | 2023 |
Patient-Level Meta-analysis of Clofarabine in Acute Lymphoblastic Leukemia.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Clinical Trials, Phase II as Topic; Clofarabine; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2023 |
[Treatment of adult Ph-negative acute lymphoblastic leukemia].
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Boronic Acids; Bortezomib; Clofarabine; Combined Modality Therapy; Consolidation Chemotherapy; Hematopoietic Stem Cell Transplantation; Histocompatibility; HLA Antigens; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrazines; Recurrence; Transplantation Conditioning; Young Adult | 2014 |
Treating adults with acute lymphocytic leukemia: new pharmacotherapy options.
Topics: Adenine Nucleotides; Adult; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Disease-Free Survival; Drug Discovery; Humans; Molecular Targeted Therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Purine Nucleosides; Pyrimidinones; Quality of Life; Recurrence; Salvage Therapy | 2016 |
The use of higher dose clofarabine in adults with relapsed acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation; Etoposide; Fatal Outcome; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Male; Mitoxantrone; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Recombinant Proteins; Recurrence; Remission Induction; Reoperation; Salvage Therapy; Vidarabine; Vincristine; Young Adult | 2009 |
The prevalent predicament of relapsed acute myeloid leukemia.
Topics: Adenine Nucleotides; Adult; Aged; Aminoglycosides; Antibodies, Monoclonal, Humanized; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Decision Making; DNA Methylation; fms-Like Tyrosine Kinase 3; Gemtuzumab; Glycine; Humans; Hydroxamic Acids; Leukemia, Myeloid, Acute; Middle Aged; Prognosis; Recurrence; Remission Induction; Risk Factors; Salvage Therapy; Stem Cell Transplantation; TOR Serine-Threonine Kinases; Transplantation, Homologous | 2012 |
Nursing considerations for clofarabine in the treatment of acute lymphoblastic leukemia in children.
Topics: Adenine Nucleotides; Arabinonucleosides; Child; Clinical Trials, Phase II as Topic; Clofarabine; Drug Administration Schedule; Drug Monitoring; Humans; Nurse's Role; Oncology Nursing; Practice Guidelines as Topic; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Remission Induction; Survival Rate; Treatment Outcome | 2006 |
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
33 trial(s) available for clofarabine and Recrudescence
| Article | Year |
|---|---|
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial.
Topics: Adult; Aged; Child; Clofarabine; Hematopoietic Stem Cell Transplantation; Humans; Neoplasm, Residual; Recurrence; Remission Induction | 2022 |
The added value of multi-state modelling in a randomized controlled trial: The HOVON 102 study re-analyzed.
Topics: Clofarabine; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Remission Induction; Treatment Outcome | 2022 |
Vorinostat Combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-Term Study Outcomes.
Topics: Acute Disease; Busulfan; Clofarabine; Drug Therapy, Combination; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine; Vorinostat | 2022 |
Phase II trial of clofarabine with topotecan, vinorelbine, and thiotepa in pediatric patients with relapsed or refractory acute leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Thiotepa; Topotecan; Vinblastine; Vinorelbine | 2014 |
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome; Young Adult | 2014 |
SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia.
Topics: Adenine Nucleotides; Adult; Aged; Antibodies, Monoclonal, Humanized; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Clofarabine; Cytarabine; Febrile Neutropenia; Female; Heart Arrest; Hematologic Diseases; Humans; Male; Middle Aged; Neoplasm, Residual; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Risk; Salvage Therapy; Sialic Acid Binding Ig-like Lectin 2; Treatment Outcome; Young Adult | 2014 |
Results from a clofarabine-busulfan-containing, reduced-toxicity conditioning regimen prior to allogeneic stem cell transplantation: the phase 2 prospective CLORIC trial.
Topics: Adenine Nucleotides; Adult; Aged; Antilymphocyte Serum; Arabinonucleosides; Busulfan; Clofarabine; Drug Administration Schedule; Female; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Biphenotypic, Acute; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous | 2014 |
Phase I/II study of clofarabine, etoposide, and mitoxantrone in patients with refractory or relapsed acute leukemia.
Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Staging; Recurrence; Remission Induction; Treatment Outcome | 2015 |
Low efficacy and high mortality associated with clofarabine treatment of relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.
Topics: Adenine Nucleotides; Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Risk Factors; Survival Rate; Time Factors | 2015 |
Sequential therapy combining clofarabine and T-cell-replete HLA-haploidentical haematopoietic SCT is feasible and shows efficacy in the treatment of refractory or relapsed aggressive lymphoma.
Topics: Adenine Nucleotides; Adult; Aged; Allografts; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retrospective Studies; Survival Rate | 2015 |
Clofarabine salvage therapy before allogeneic hematopoietic stem cell transplantation in patients with relapsed or refractory AML: results of the BRIDGE trial.
Topics: Adenine Nucleotides; Adult; Aged; Antimetabolites, Antineoplastic; Arabinonucleosides; Clofarabine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Prospective Studies; Recurrence; Salvage Therapy; Transplantation, Homologous | 2016 |
Efficacy, safety and pharmacokinetics of clofarabine in Chinese pediatric patients with refractory or relapsed acute lymphoblastic leukemia: a phase II, multi-center study.
Topics: Adenine Nucleotides; Adolescent; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Drug Resistance, Neoplasm; Humans; Infant; Infant, Newborn; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome | 2016 |
Phase 1 study of clofarabine in pediatric patients with relapsed/refractory acute lymphoblastic leukemia in Japan.
Topics: Adenine Nucleotides; Adolescent; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Dose-Response Relationship, Drug; Half-Life; Humans; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome | 2016 |
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adenine Nucleotides; Adolescent; Antineoplastic Agents; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Drug Resistance, Neoplasm; Female; Fever; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Male; Nausea; Neutropenia; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2009 |
Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cyclophosphamide; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome | 2009 |
A phase I trial of high-dose clofarabine, etoposide, and cyclophosphamide and autologous peripheral blood stem cell transplantation in patients with primary refractory and relapsed and refractory non-Hodgkin lymphoma.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Clofarabine; Combined Modality Therapy; Cyclophosphamide; Etoposide; Female; Filgrastim; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematologic Diseases; Hematopoietic Stem Cell Mobilization; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Recurrence; Salvage Therapy; Transplantation, Autologous; Treatment Outcome | 2011 |
Southwest Oncology Group Study S0530: a phase 2 trial of clofarabine and cytarabine for relapsed or refractory acute lymphocytic leukaemia.
Topics: Adenine Nucleotides; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Connective Tissue Growth Factor; Cytarabine; Female; Humans; Male; Neoplasm Proteins; Nucleoside Transport Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Treatment Outcome | 2010 |
Report of a phase II study of clofarabine and cytarabine in de novo and relapsed and refractory AML patients and in selected elderly patients at high risk for anthracycline toxicity.
Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Drug Administration Schedule; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Patient Selection; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome | 2011 |
Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Arabinonucleosides; Clofarabine; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Retreatment; Rituximab; Salvage Therapy | 2011 |
Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Benzenesulfonates; Child; Clofarabine; Cytarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Recurrence; Sorafenib | 2011 |
Phase 2 trial of clofarabine in combination with etoposide and cyclophosphamide in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cyclophosphamide; Etoposide; Female; Humans; Infant; Kaplan-Meier Estimate; Male; Nucleoside Transport Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Risk Factors; RNA, Messenger; Young Adult | 2011 |
Phase I-II study of clofarabine-melphalan-alemtuzumab conditioning for allogeneic hematopoietic cell transplantation.
Topics: Acute Kidney Injury; Adenine Nucleotides; Adult; Age Factors; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Female; Glomerular Filtration Rate; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Recurrence; Risk; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous | 2012 |
A phase I dose-escalation study of clofarabine in combination with fractionated gemtuzumab ozogamicin in patients with refractory or relapsed acute myeloid leukemia.
Topics: Acute Disease; Adenine Nucleotides; Adult; Alanine Transaminase; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Aspartate Aminotransferases; Clofarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gemtuzumab; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Neutropenia; Recurrence; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Clofarabine, cyclophosphamide and etoposide for the treatment of relapsed or resistant acute leukemia in pediatric patients.
Topics: Acute Disease; Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Clofarabine; Cyclophosphamide; Drug Administration Schedule; Etoposide; Female; Gastrointestinal Diseases; Humans; Infant; Kaplan-Meier Estimate; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Remission Induction; Treatment Outcome | 2012 |
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Placebos; Recurrence | 2012 |
Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prospective Studies; Recurrence; Remission Induction; Salvage Therapy; Treatment Outcome; Young Adult | 2012 |
Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias.
Topics: Acute Disease; Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cyclophosphamide; DNA Damage; Drug Administration Schedule; Female; Humans; Leukemia; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Young Adult | 2012 |
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Dose-Response Relationship, Drug; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2012 |
Oral clofarabine for relapsed/refractory non-Hodgkin lymphomas: results of a phase 1 study.
Topics: Adenine Nucleotides; Administration, Oral; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Arabinonucleosides; CD4 Lymphocyte Count; Clofarabine; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Tumor Burden | 2013 |
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia.
Topics: Adenine Nucleotides; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Recurrence; Survival Rate; Treatment Outcome | 2003 |
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias.
Topics: Acute Disease; Adenine Nucleotides; Aged; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Karyotyping; Leukemia; Male; Middle Aged; Recurrence; Treatment Outcome | 2005 |
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Female; Humans; Infant; Infusions, Intravenous; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome | 2006 |
Clinical and pharmacokinetic study of clofarabine in chronic lymphocytic leukemia: strategy for treatment.
Topics: Adenine Nucleotides; Aged; Arabinonucleosides; Clofarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocytes; Male; Maximum Tolerated Dose; Middle Aged; Molecular Structure; Neoplasm Staging; Recurrence; Tissue Distribution; Treatment Outcome | 2006 |
28 other study(ies) available for clofarabine and Recrudescence
| Article | Year |
|---|---|
Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen.
Topics: Busulfan; Child; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Recurrence; Vidarabine | 2022 |
Clofarabine with topotecan, vinorelbine, and thiotepa reinduction regimen for children and young adults with relapsed AML.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Child; Clofarabine; Humans; Leukemia, Myeloid, Acute; Recurrence; Thiotepa; Topotecan; Vinorelbine; Young Adult | 2022 |
Clofarabine and Busulfan Myeloablative Conditioning in Allogeneic Hematopoietic Cell Transplantation for Patients With Active Myeloid Malignancies.
Topics: Adult; Aged; Busulfan; Clofarabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myeloablative Agonists; Myeloproliferative Disorders; Recurrence; Retrospective Studies; Transplantation, Homologous; Young Adult | 2023 |
Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia.
Topics: Adenine Nucleotides; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Area Under Curve; Clofarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Liver; Liver Function Tests; Male; Middle Aged; Recurrence; Skin; Treatment Outcome | 2017 |
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Bone Marrow; Clofarabine; Cyclophosphamide; Disease-Free Survival; Female; Fusion Proteins, bcr-abl; Graft vs Host Disease; Humans; Imidazoles; Immunophenotyping; Mutation; Neoplasm, Residual; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prednisone; Protein Kinase Inhibitors; Pyridazines; Recurrence; Salvage Therapy; Transplantation, Homologous | 2017 |
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase II as Topic; Clofarabine; Cohort Studies; Cytarabine; DNA, Neoplasm; Female; High-Throughput Nucleotide Sequencing; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Recurrence; Sequence Analysis, DNA; Vidarabine | 2018 |
Long-term Survival and Value of Chimeric Antigen Receptor T-Cell Therapy for Pediatric Patients With Relapsed or Refractory Leukemia.
Topics: Adolescent; Antimetabolites, Antineoplastic; Child; Chronic Disease; Clofarabine; Cost-Benefit Analysis; Humans; Immunotherapy, Adoptive; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Quality-Adjusted Life Years; Receptors, Antigen, T-Cell; Receptors, Chimeric Antigen; Recurrence; Treatment Outcome; Young Adult | 2018 |
Impact of genotype in relapsed and refractory acute myeloid leukaemia patients treated with clofarabine and cytarabine: a retrospective study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Clofarabine; Cytarabine; Drug Administration Schedule; Female; Follow-Up Studies; Genotype; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Prognosis; Recurrence; Retrospective Studies; Salvage Therapy; Survival Analysis; Young Adult | 2019 |
[Therapeutic effect of clofarabine in children with relapsed or refractory acute lymphoblastic leukemia].
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Agents; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Female; Follow-Up Studies; Humans; Infant; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence | 2013 |
Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease.
Topics: Adenine Nucleotides; Adolescent; Antimetabolites, Antineoplastic; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Female; Histiocytosis, Langerhans-Cell; Histiocytosis, Sinus; Humans; Infant; Male; Recurrence; Salvage Therapy; Xanthogranuloma, Juvenile | 2014 |
Clofarabine-based combination chemotherapy for relapse and refractory childhood acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Adolescent; Analgesics, Opioid; Antibiotic Prophylaxis; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cefazolin; Child; Clofarabine; Cyclophosphamide; Etoposide; Fentanyl; Humans; Induction Chemotherapy; Male; Pain; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Shock, Septic; Systemic Inflammatory Response Syndrome; Treatment Outcome | 2014 |
Control of relapsed or refractory acute myeloid leukemia by clofarabine in preparation for allogeneic stem cell transplant.
Topics: Adenine Nucleotides; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retreatment; Retrospective Studies; Salvage Therapy; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Young Adult | 2015 |
Sustained responses after clofarabine-based sequential allogeneic stem cell transplantation in children with high-risk, relapse and/or refractory acute myeloid leukemia or juvenile myelomonocytic leukemia: a study on behalf of the French society of bone m
Topics: Adenine Nucleotides; Adolescent; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Combined Modality Therapy; Female; France; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile; Male; Recurrence; Retrospective Studies; Risk Factors; Transplantation, Homologous; Treatment Outcome; Young Adult | 2016 |
A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia.
Topics: Adenine Nucleotides; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Cause of Death; Clofarabine; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Treatment Outcome | 2017 |
HLA haploidentical hematopoietic cell transplantation using clofarabine and busulfan for refractory pediatric hematological malignancy.
Topics: Adenine Nucleotides; Arabinonucleosides; Busulfan; Child; Clofarabine; Female; Follow-Up Studies; Haploidy; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Leukemia; Male; Recurrence; Remission Induction; Time Factors; Transplantation Conditioning; Treatment Outcome | 2017 |
Clofarabine-based chemotherapy as a bridge to transplant in the setting of refractory or relapsed acute myeloid leukemia, after at least one previous unsuccessful salvage treatment containing fludarabine: a single institution experience.
Topics: Adenine Nucleotides; Adolescent; Adult; Aged; Allografts; Arabinonucleosides; Clofarabine; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Vidarabine | 2017 |
Clofarabine in relapsed lymphoma: what is the optimal dose?
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clinical Trials as Topic; Clofarabine; Data Interpretation, Statistical; Drug Administration Schedule; Humans; Lymphoma, Non-Hodgkin; Medical Oncology; Recurrence; Remission Induction; Research Design | 2009 |
Advanced Philadelphia chromosome positive acute lymphoblastic leukemia patients relapsed after treatment with tyrosine-kinase inhibitors: successful response to clofarabine and cyclophosphamide.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclophosphamide; Female; Humans; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Protein Kinase Inhibitors; Recurrence | 2009 |
Clofarabine-based salvage chemotherapy for relapsed or refractory acute leukemia before allogeneic stem cell transplantation: results from a case series.
Topics: Acute Disease; Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cyclophosphamide; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myelomonocytic, Acute; Male; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2009 |
Remission re-induction chemotherapy with clofarabine, topotecan, thiotepa, and vinorelbine for patients with relapsed or refractory leukemia.
Topics: Adenine Nucleotides; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Topotecan; Vinblastine; Vinorelbine | 2010 |
Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia.
Topics: Adenine Nucleotides; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Treatment Outcome; Young Adult | 2011 |
Infections in relapsed or refractory acute myeloid leukemia patients given clofarabine+cytarabine.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Clofarabine; Cytarabine; Drug Resistance, Neoplasm; Humans; Infections; Leukemia, Myeloid, Acute; Recurrence; Treatment Failure | 2011 |
Early UK experience in the use of clofarabine in the treatment of relapsed and refractory paediatric acute lymphoblastic leukaemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Drug Evaluation; Female; Humans; Infant; Infant, Newborn; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Treatment Outcome | 2011 |
Institutional experience with clofarabine and cytarabine in relapsed pediatric acute myeloid leukemia.
Topics: Adenine Nucleotides; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Child; Child, Preschool; Clofarabine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Recurrence; Retrospective Studies; Transplantation, Homologous | 2012 |
Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy.
Topics: Adenine Nucleotides; Adult; Aged; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Oncogene Proteins, Fusion; Recurrence; Remission Induction; Survival Analysis; Treatment Outcome | 2012 |
Saccharomyces cerevisiae emboli in an immunocompromised patient with relapsed acute myeloid leukaemia.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Clofarabine; Dermatomycoses; Female; Humans; Immunocompromised Host; Leukemia, Myeloid, Acute; Middle Aged; Opportunistic Infections; Recurrence; Saccharomyces cerevisiae | 2007 |
Clofarabine induced durable complete remission in heavily pretreated adolescents with relapsed and refractory leukemia.
Topics: Acute Disease; Adenine Nucleotides; Adolescent; Arabinonucleosides; Clofarabine; Female; Humans; Leukemia, Myeloid; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Remission Induction | 2007 |
Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Bone Marrow Neoplasms; Clinical Trials as Topic; Clofarabine; Drug Administration Schedule; Drug Resistance, Neoplasm; Humans; Immunophenotyping; Leukemia-Lymphoma, Adult T-Cell; Male; Recurrence; Skin Neoplasms; Stem Cell Transplantation; Transplantation, Homologous; Treatment Outcome | 2006 |